Granulocyte-colony stimulating factor therapy (G-CSF) should be used as primary or secondary prophylaxis for neutropenia and erythropoiesis-stimulating agents (ESA) can be used to manage anemia which does not respond to treatment. This evidence concerns the gene CSF3 and anemia.